Pembrolizumab Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy

KEYNOTE-427 is a single-arm, open-label, non-randomized, multi-cohort, Phase 2 study evaluating the safety and efficacy of KEYTRUDA as monotherapy in patients with advanced RCC who have not received prior systemic therapy.06/13/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news